BioTuesdays

Category - Markets

Viveve Medical Logo
Markets

Stifel cuts Viveve Medical to hold; PT to $1 from $3

Stifel downgraded Viveve Medical (NASDAQ:VIVE) to “hold” from “buy” and lowered its price target to $1 from $3 after the company’s LIBERATE-International trial for stress urinary incontinence (SUI) missed its primary...

July 23, 2019
Markets

WB starts Change Healthcare at OP

William Blair launched coverage of Change Healthcare (NASDAQ:CHNG) with an “outperform” rating. The stock closed at $13.50 on July 19. Change Healthcare is a leading healthcare technology platform provider, offering...

July 22, 2019
Precision Biosciences
Markets

HCW starts Precision BioSciences at buy; PT $21

H.C. Wainwright initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $13.76 on July 15. Precision is one of the early adopters of a potential paradigm...

July 16, 2019
Markets

Roth starts Akero Therapeutics at buy; PT $34

Roth Capital Partners initiated coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and price target of $34. The stock closed at $19.88 on July 12. “Although Akero’s lead asset, AKR-001 (a FGF21...

July 15, 2019
Syros-Logo
Markets

Roth resumes coverage of Syros Pharma at buy; PT $17

Roth Capital Partners resumed coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and $17 price target. The stock was quoted at $8.49 in afternoon trading on July 12. Syros was co-founded by ARCH Venture...

July 12, 2019
rhythm pharmaceuticals
Markets

Stifel ups Rhythm Pharma to buy; PT held at $34

Stifel upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to “buy” from “hold” but maintained its price target at $34, saying the stock is at an attractive entry point ahead of near-term Phase 3 results. The stock closed at...

July 12, 2019
maxim Group Logo
Markets

Maxim cuts PTs on five biotech stocks

Maxim Group reduced price targets for five biotech stocks, citing data troughs, financing conditions and political factors, which may be further compounded by a lack of catalysts and increasing operating expenses...

July 9, 2019